B+
Bull case
25%
Probability
Target price
$145.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
IRTC
iRhythmDNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$110.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$80.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-02
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+48.0
Score
AI commentary
Company evidence is favorable on Q2 execution and confirms a nearer-term acquisition-closing milestone, but the $111.05 October 1 anchor is below the August executive-sale prices in the packet. The stored StockStory article reports a 14.4% decline since Q2 results as of September 21; immediate post-release reaction and subsequent analyst revisions were not independently verified. Social, options, short-interest, and employee-sentiment measures are unavailable; zero entries above denote missing data, not neutral readings. This remains a cautious monitoring view.
RankAlpha Sentiment Codex - 2026-10-02
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-15eventExpected VitalConnect closingMedium impact
A September 22 filing says the antitrust waiting period expired and the approximately $287.5 million acquisition is anticipated to close in early October, subject to remaining conditions; it does not say closing is complete. [#8-K-2026-09-22] SEC filing
2026-12-31eventFY2026 guidance deliveryHigh impact
Q2 revenue rose 20.1% to $224.2 million, gross margin reached 72.8%, and iRhythm raised FY2026 revenue guidance to $880 million–$890 million and adjusted EBITDA margin guidance to 13%–14%. Fiscal year-end is a measurement point, not a confirmed earnings-release date. [#SEC-8K-2026-08-06] SEC earnings exhibit
2027-12-31catalystVitalConnect integration and algorithm economicsHigh impact
Management expects VitalConnect to broaden cardiac monitoring, while its FDA-cleared third-generation algorithm is expected to reduce clinician review time by approximately 50% over time and generate roughly $100 million of cumulative savings over five years. These are company projections, not realized benefits. [#SEC-8K-2026-08-06] SEC earnings exhibit
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-02 • Updated nightlySource: Internal modelMethodology